Ipriflavone promotes osteogenesis of MSCs derived from osteoporotic rats

Area of Science:

• Biomedical Science
• Cell Biology
• Osteoporosis Research

Background:

• Postmenopausal osteoporosis (PMOP) is a significant health concern characterized by decreased bone quality.
• Mesenchymal stem cells (MSCs) play a crucial role in bone formation and regeneration.
• Therapeutic strategies targeting osteogenesis are vital for managing PMOP.

Purpose of the Study:

• To investigate the potential of Ipriflavone in preventing PMOP.
• To determine if Ipriflavone enhances osteogenesis in bone marrow-derived MSCs.
• To evaluate Ipriflavone's effect on bone quality and biomechanical properties in an osteoporosis model.

Main Methods:

• Rat bone marrow-derived MSCs were isolated, identified, and treated with Ipriflavone.
• Osteogenic and adipogenic gene expression was analyzed using qRT-PCR.
• Cell proliferation, alkaline phosphatase activity, mineralization, and protein expression were assessed.
• An ovariectomized rat model was used to evaluate in vivo effects on bone mineral density (BMD) and biomechanical properties.

Main Results:

• Ipriflavone at 0.8 μM was found to be non-cytotoxic to MSCs.
• In vitro studies demonstrated that Ipriflavone significantly promoted MSC osteogenesis.
• In vivo, Ipriflavone treatment prevented the decrease in BMD, BV/TV, Tb.N, and Tb.Th in ovariectomized rats.
• Ipriflavone treatment effectively counteracted bone loss and improved bone structure in the osteoporosis model.

Conclusions:

• Ipriflavone demonstrates significant potential in preventing and treating postmenopausal osteoporosis.
• The mechanism involves the promotion of osteogenesis by bone marrow-derived MSCs.
• Ipriflavone improves bone quality and protects bone tissue, offering a promising therapeutic agent for PMOP.